Athersys (NASDAQ:ATHX) is set to post its quarterly earnings results after the market closes on Tuesday, November 6th. Analysts expect Athersys to post earnings of ($0.08) per share for the quarter.
Athersys (NASDAQ:ATHX) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported $0.05 EPS for the quarter. Athersys had a negative return on equity of 61.52% and a negative net margin of 106.99%. The business had revenue of $19.39 million during the quarter, compared to analysts’ expectations of $12.82 million. On average, analysts expect Athersys to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Athersys stock opened at $1.90 on Tuesday. Athersys has a 12 month low of $1.29 and a 12 month high of $3.09. The company has a market cap of $268.85 million, a PE ratio of -6.55 and a beta of -0.61.
A number of brokerages recently weighed in on ATHX. Zacks Investment Research lowered Athersys from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 9th. BidaskClub raised Athersys from a “sell” rating to a “hold” rating in a report on Wednesday, September 26th. Finally, Maxim Group reaffirmed a “buy” rating and set a $6.00 price objective on shares of Athersys in a report on Wednesday, August 8th.
Athersys Company Profile
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Recommended Story: Bear Market – How and Why They Occur
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.